Derm

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study

YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ViralResearch Corp. (OTCBB: ADVR), a research based biopharmaceuticalcompany, announced today that preliminary findings from its ongoingPhase II dermatological study show topical treatment with AVR118appears to have clinical activity in reducing inflammation andredness associated with surgical incisions or dermatologicdermabrasion....

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., aprivately held specialty pharmaceutical company, today announcedpositive results from an initial Phase I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines NuPathe's SmartRelief(TM) proprietaryiontophoretic transdermal technology with sumatriptan, the mostwidely prescri...

Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today that DAYTRANA(TM) (methylphenidate transdermalsystem), its Attention Deficit Hyperactivity Disorder (ADHD) patch,had significant efficacy in reducing the symptoms of ADHD in bothmale and female children aged 6 to 12 years, according to clinicaltrial results reported at the American Psychiatric Association(APA) ann...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced that DAYTRANA(TM) (methylphenidate transdermal system),the first and only non-oral medication approved for treatment ofAttention Deficit Hyperactivity Disorder (ADHD) in children aged 6to 12 years, provided significant improvement in symptom controland tolerability, according to results of a 12-month open-labelstudy pre...

Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

BASEL, Switzerland, May 21, 2007 - Results from phase IIIclinical trials and further human pharmacology studies werepresented at the 16th Congress of the European Academy ofDermatology and Venereology (EADV). These data highlighted theefficacy and safety profile of alitretinoin as a potential oncedaily oral treatment for patients with severe refractory chronichand eczema. Currentl...

AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage

Clinical Poster Presented at Society for Investigative Dermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire/ -- AGI Dermaticsrecently announced new comparative clinical data that indicatesthat OCTN-1 skin cells have the ability to recognize, transport andutilize L-ergothioneine (EGT) as a protector against oxidativedamage, and importantly, that (EGT) acts as a more powerful andefficient a...

AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells

Clinical Data Presented at the Society for InvestigativeDermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire-FirstCall/ -- AGIDermatics today announced new clinical research that the8-oxo-guanine DNA glycosylase (OGG1) encapsulated in liposomesenhances DNA repair and reduces MMP-1 and TNF-alpha in UVirradiated skin cells. The data was presented at the 68th AnnualMeeting of the Society fo...

Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today that the Companyintends to initiate a Phase 1b clinical trial to demonstrate theefficacy and safety of the improved formulation of its transdermalinsulin product, TPM-02/Insulin, containing long-acting insulin.The trial is expected to commence in the second quarter of2007....

Laresse Dermal Filler Research Presented at Anti-Aging World Congress

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - FzioMed,Inc. announced today that a review of the company's research onnovel, synthetic dermal fillers is being presented at theAnti-Aging Medical World Congress (AAMWC) in Monte Carlo March22-24, 2007. In 2006, FzioMed launched Laresse Dermal Filler, the firstultra-smooth, non-permanent, synthetic filler created from thecompany's...